ראשי » About Multiple Sclerosis » Therapeutic information by pharmaceutical companies » Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study

Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study

Updated 08.08.2014
  • Data from single-arm extension of head-to-head TRANSFORMS study show sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment for up to 4.5 years
  • Reductions in relapses and MRI measures were observed in patients
  • Extension study results demonstrated once-daily oral Gilenya was generally well-tolerated with a safety profile consistent with pivotal trials
  • As of February 2012, approximately 36,000 patients have been treated in clinical trials and in the post-marketing setting

Basel, June 11, 2012 – New long-term data for Gilenya® (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment1.

“These data further reinforce our confidence in Gilenya’s long-term effectiveness and safety profile. The TRANSFORMS extension study shows that MS patients treated continuously with Gilenya for up to four and a half years demonstrated sustained low levels of clinical and MRI activity,” said Tim Wright, Global Head of Development, Novartis Pharma. “Furthermore, patients who switched to Gilenya showed a reduction in relapses and improvements in MRI measures in the extension compared to the core study.”

Patients in the switch group also displayed a slowing of brain atrophy following the switch to Gilenya.

These data were presented at the 22nd Annual Meeting of the European Neurological Society (ENS), taking place 9-12 June 2012 in Prague, Czech Republic.

22 January 2024

All the practices teach us to start with the silence, the peace and the light that we have within ourselves. Obviously, external situations change and

29 October 2023

EBV infection and its relation to MS is an interesting area of ongoing work. What is EBV? The Epstein-Barr virus (EBV) is one of the

15 July 2023

Telling people that you have MS can be difficult. Accepting the diagnosis yourself is hard, let alone sharing the news with others. Being able to

13 July 2023

Smokers are more likely to progress from relapsing-remitting to progressive MS than non-smokers and have higher levels of long-term disability. Smokers with clinically isolated syndrome

13 July 2023

Menopause is the natural end to a woman’s periods (menstruation). It usually occurs between the ages of 45 and 55 years. Why discuss MS and

13 July 2023

MS is complex and can cause many different symptoms. Early MS may present itself as a history of vague symptoms, which may occur sporadically over a

05 March 2023

No need to pay out of pocket! PassportCard is a cashless system that pays for your medical expenses! Full exemption from deductibles on medical expenses

Previous Next
Close
Test Caption
Test Description goes like this